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The Systemic Response to Topical 
Aldara Treatment is Mediated 
Through Direct TLR7 Stimulation as 
Imiquimod Enters the Circulation
Louis Nerurkar  1, Alison McColl1, Gerard Graham1 & Jonathan Cavanagh2
Topical application of Aldara cream, containing the Toll-like receptor 7/8 agonist Imiquimod, is a widely 
used mouse model for investigating the pathogenesis of psoriasis. We have previously used this model 
to study the effects of peripheral inflammation on the brain, and reported a brain-specific response 
characterised by increased transcription, infiltration of immune cells and anhedonic-like behavior. Here, 
we perform a more robust characterisation of the systemic response to Aldara application and find a 
potent but transient response in the periphery, followed by a prolonged response in the brain. Mass 
spectrometry analysis of plasma and brain samples identified significant levels of Imiquimod in both 
compartments at molar concentrations likely to evoke a biological response. Indeed, the association 
of Imiquimod with the brain correlated with increased Iba1 and GFAP staining, indicative of microglia 
and astrocyte reactivity. These results highlight the potency of this model and raise the question of how 
useful it is for interpreting the systemic response in psoriasis-like skin inflammation. In addition, the 
potential impact on the brain should be considered with regards to human use and may explain why 
fatigue, headaches and nervousness have been reported as side effects following prolonged Aldara use.
Aldara cream is most commonly used for the topical treatment of external genital warts, actinic keratosis and 
superficial basal cell carcinoma. Its active component, Imiquimod (IMQ), is a TLR7/8 agonist that induces a 
potent anti-viral response characterised by the production of type I interferons (IFN), pro-inflammatory 
cytokines and chemokines1. Its clinical use highlighted common local side effects including erythema, swelling, 
scabbing and itching of the skin2,3 and it was subsequently tested in rodents as a potential model of psoriasis. As 
such, the Aldara model of psoriasis-like skin inflammation was first described in 2009 by Van Der Fits et al. and 
has since become one of the most widely used models in preclinical psoriasis studies4.
Since 2009, many studies have examined the pathogenesis of this model at the site of application. It is now 
thought that the response to Aldara cream is mediated primarily through CD4+ T cells, specifically Th17 cells and 
intradermal γδ-T cells in an IL-17/IL-23-dependent manner, much like human psoriasis4,5. The skin response is 
characterised by local type I IFN and pro-inflammatory cytokine production, immune cell infiltration into the 
skin and hyperkeratosis.
In addition to the local skin response, topical Aldara application was noted to cause systemic pro-inflammatory 
cytokine production and enlarged spleen and draining lymph nodes4,6. As such, as well as its use for studying 
psoriasis-like inflammation in the local tissue, the Aldara model has been used to investigate the systemic effects 
of psoriatic inflammation. For example, Hackstein et al. used topical Aldara treatment to examine the effects of 
skin TLR7 antagonism on respiratory leukocyte populations7. Alongside them, Al-Harbi et al. have used this 
model to demonstrate psoriasis-induced hepatic inflammation8. In addition, we have previously used the Aldara 
model to investigate the systemic effects of IMQ and TLR7 activation, with a particular focus on the distal brain 
response6,9. We have shown that topical Aldara treatment induced a transcriptional interferon stimulated gene 
(ISG) and chemokine response in what appeared to be a brain-specific manner, along with the infiltration of 
immune cells into the brain, a reduction in hippocampal neurogenesis and a reduction in burrowing behaviour.
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The precise mechanisms underpinning this brain response were of great interest to us, as many potential 
routes of communication exist between the periphery and the brain10. For example, IMQ could activate TLR7 
on peripheral nerves, transmitting the inflammatory signal through the neural pathway11. Alternatively, 
pro-inflammatory cytokines and other soluble mediators could enter the circulation and reach the brain either 
by active transport across, or disruption of, the blood-brain-barrier10. Finally, if IMQ was able to enter the circu-
lation and the brain directly, several brain-resident cells types including microglia, astrocytes and neurons, have 
been shown to express TLR7 and would therefore be able to respond directly12,13.
A growing literature clearly points towards the existence of a systemic response following topical Aldara treat-
ment, however this was not particularly apparent in our previous studies. Whilst the PBL response was inves-
tigated alongside the brain as an indicator of systemic inflammation, the extent of the response was difficult to 
assess as we did not characterise a range of peripheral tissues or early time-points. Therefore, the aim of this study 
was to systematically characterise the tissue response to Aldara treatment across a detailed time-course model to 
determine the most likely mechanism driving systemic inflammation. An early transcriptional response through-
out all peripheral tissues prompted further investigation regarding the capacity of IMQ to enter the circulation, 
and subsequently the brain. Our findings, presented in this current study, show IMQ is present in both the plasma 
and brain as early as 4 hours after treatment, suggesting the primary mechanism of immune activation of topical 
Aldara treatment is through the direct ligation of IMQ with TLR7 receptors throughout the body.
Results
Topical Aldara application induces a transcriptional chemokine and cytokine response in the 
brain as early as four hours after treatment. Having previously shown that topical Aldara treatment 
induces a transcriptional response in the brain that peaks 3–5 days after treatment, we sought to determine the 
temporal mechanisms of the brain response. To do so, we performed a detailed time course analysis incorporating 
4 hr, 12 hr, 1 day, 3 days and 5 days post-treatment, analysing a panel of 8 chemokines (Fig. 1A) and 4 cytokines 
(Fig. 1B) using QRT-PCR. The time course model showed that multiple chemokine transcripts were upregulated 
as early as 4 hr after treatment, including statistically significant increases in levels of Ccl2, Ccl5 and Cxcl10. By 
1 day, Ccl3, Ccl4 and Cxcl13 were also significantly raised in the brain when compared with controls. In keeping 
Figure 1. Topical Aldara application induces a chemokine and cytokine transcriptional response in the brain 
as early as 4 hours after treatment. QRT-PCR analysis was performed on RNA from perfused brain samples 
from mice treated daily with Aldara or control cream. Samples were collected 4 hr, 12 hr, 1 d, 3 d and 5 d after 
the initial treatment. The expression profile of 8 chemokines (A) and 4 cytokines (B) was assessed. Expression 
values were normalized to housekeeping gene Tbp. Data are presented as mean (+/−SD) fold changes vs 
respective controls. N = 4 mice per group. Data were log transformed and significance was determined using 
one-way ANOVA with post-hoc Student’s t-test with Bonferroni’s multiple testing correction. *P < 0.05; 
**P < 0.01; ***P < 0.001.
www.nature.com/scientificreports/
3Scientific REpoRTS | 7: 16570  | DOI:10.1038/s41598-017-16707-5
with our previous findings, 3 days appeared to be the peak of the transcriptional response where all chemokines 
were significantly upregulated. Between 3 and 5 days, this response began to ameliorate, however the expression 
of all but Cxcl1 remained significantly higher in the brains of Aldara treated mice at day 5. With regard to the 
cytokine transcripts (Fig. 1B), Tnfa appeared to be the earliest induced in the brain, with a significant increase 
from 12 hr after treatment through to 5 days. Il6 was significantly induced 1 day after treatment and by 3 days Il1b, 
Tnfa, Il6 and Il10 were all significantly upregulated in the brains of treated mice. Interestingly Il10, a cytokine 
considered to mediate anti-inflammatory effects, did not significantly increase until 3 days, but remained signif-
icantly elevated at 5 days, perhaps indicating a delayed resolution of the brain response. As Il-17 and Il-23 have 
previously been associated with the dermal response to IMQ we also assessed their expression in the brain4. Il-17 
was not detectable and Il-23a was not found to differ significantly between treated and control groups at any time-
point (Supplementary Figure 1).
The transcriptional chemokine and cytokine response in the brain following topical Aldara 
treatment is translated into protein. Topical Aldara treatment induced a marked increase in a number 
of chemokine and cytokine gene transcripts in the brain throughout the time course model. To determine the 
biological relevance of this response, protein levels of 8 chemokines and 4 cytokines were measured in brain 
homogenate (Fig. 2A and B, respectively) 4 hr, 12 hr, 1 day, 3 days and 5 days after treatment. CCL11, CXCL1 
and CXCL10 displayed significantly elevated levels of expression in the brain at 4 hr and 12 hr after Aldara treat-
ment when compared with controls. By 1 day, all chemokines analysed, including CCL2, CCL3, CCL4, CCL5 
and CXCL13, were significantly upregulated in the brains of treated mice. These remained raised until day 3, at 
which point several of the chemokines were being expressed at levels between 100–1000 pg/ml. By 5 days, the 
protein levels tended to decrease, however CCL3, CCL4, CCL5, CCL11, CXCL1, CXCL10 and CXCL13 remained 
significantly higher than control levels. With regards to cytokine expression, IL-6 was the first to be upregulated 
in the brain and was significantly induced at 4 hr and 12 hr. By 1 day, TNFα was also significantly upregulated in 
the brains of Aldara treated mice. The highest level of induction of cytokines occurred at day 3, when all cytokines 
analysed were significantly induced, however by day 5, IL-1β was the only cytokine to remain significantly raised 
Figure 2. Topical Aldara application induces a chemokine and cytokine protein response in the brain as early 
as four hours after treatment. Biolegend LegendPlex protein array analysis was performed on perfused brain 
samples from mice treated daily with Aldara or control cream. Samples were collected 4 hr, 12 hr, 1 d, 3 d and 
5 d after initial treatment. The expression profile of 8 chemokines (A) and 4 cytokines (B) was assessed. Samples 
below the limit of detection were set to the limit of detection. N = 4 mice per group. Data are presented as mean 
(+/−SD) of absolute protein values. Data were log transformed and significance was determined using one-
way ANOVA with post-hoc Student’s t-test with Bonferroni’s multiple testing correction. *P < 0.05; **P < 0.01; 
***P < 0.001.
www.nature.com/scientificreports/
4Scientific REpoRTS | 7: 16570  | DOI:10.1038/s41598-017-16707-5
in the treated mice. In addition to the cytokines shown in Fig. 2B, the protein assay allowed us to measure IFNβ 
and IFNγ in the brain, both of which were significantly induced at day 3 (Supplementary Figure 2). Surprisingly, 
the protein expression of CCL11 and CXCL1 was significantly induced at all time-points despite this increase not 
being reflected at the transcript level.
Topical Aldara application induces a transcriptional response in systemic tissues that is tempo-
rally unique compared with the brain. In previous studies we have compared the brain response with the 
peripheral blood leukocyte (PBL) response as an indicator of systemic inflammation following Aldara treatment. 
The results showed very little upregulation of expression, however the earliest time point investigated was 24 hr. 
To determine if Aldara treatment induces an early systemic response, we assessed a number of peripheral organs, 
including the skin (A), PBL (B), liver (C) and lungs (D), at 4 hr, 12 hr, 24 hr, 72 hr and 120 hr post-treatment. 
We have focused on three classic inflammatory chemokines, Ccl2, Ccl5 and Cxcl10 (Fig. 3A–D), and three 
archetypal cytokines Il1b, Tnfa and Il10 (Fig. 4A–D), although a more detailed panel of genes were investigated 
(Supplementary Figures 3–6). Both the PBL and the lungs exhibited significant upregulation of Ccl2, Ccl5, Cxcl10, 
Il1b, Tnfa and Il10 at 4 hours after treatment. Cxcl10 was the gene with the biggest fold change induction com-
pared to control mice, with a striking 500-fold increase in the PBL and almost 1000-fold increase in the lungs. 
With the exception of Il1b, all genes were significantly upregulated in the liver at 4 hours. The skin displayed the 
highest degree of variation, although all three chemokines were significantly induced at 4 hours and 12 hours 
after treatment. Interestingly, Il1b and Tnfa failed to reach significance despite an upward trend and Il10 was only 
significantly higher at 12 hours after treatment. Whilst the peripheral tissues displayed a strong response at the 
earlier time points, the response tended to ameliorate over the course of the model and by day 3, many cytokines 
and chemokines were close to control levels.
Imiquimod enters the circulation and the brain within 4 hours of topical Aldara application. 
Topical Aldara treatment induces a potent transcriptional response throughout peripheral tissues including the 
skin, PBL, lungs and liver. This was evident within 4 hours of treatment, indicating a very rapid dissemination 
of the immune response. With this in mind, it was important to determine if the active component, IMQ, was 
entering the circulation, and subsequently the CNS. To address this question, plasma and perfused brains were 
extracted from mice treated with Aldara cream for 3 days, in line with the peak transcriptional and protein 
response in the brain. Results showed that IMQ was present in both the plasma and brain at 3 days, in quantities 
equal to 0.33 μM (95% CI; 0.15–0.52) in the plasma with a total load of 0.76 nmol (95% CI; 0.31–1.21 nmol) in 
the brain (Fig. 5A). To determine the temporal nature of IMQ dissemination throughout the plasma and brain, 
we assessed three earlier time points, 4 hr, 12 hr and 24 hr after treatment. Consistent with the 3 day results, IMQ 
was present in both compartments at all time points analysed, and reached significant levels at 12 hr, 24 hr and 3 
days when compared with levels in control mice (Fig. 5B). Correlation analysis was performed to determine the 
relationship between plasma levels and brain levels of IMQ, showing a very strong positive relationship with an 
r2 equal to 0.9 (Fig. 5C).
IMQ entry into the CNS is associated with reactive gliosis. We have previously reported that Aldara 
application is associated with immune cell infiltration into the CNS; however the response of brain-resident 
immune cells has not yet been evaluated. With the knowledge that IMQ can reach the brain, it was important 
to determine the response of resident cells that express TLR7 receptors, namely microglia and astrocytes. Using 
Iba1 and GFAP respectively, the response of microglia and astrocytes was assessed using immunohistochemistry 
at 1 day and 3 days after application. With regards to the Iba1 staining (Fig. 6A), there were clear morphological 
differences between the control and treated brains, with treated cells displaying thickened processes and altera-
tions in ramification. As we had previously identified changes in hippocampal neurogenesis in response to Aldara 
treatment, we chose to quantify Iba1 and GFAP staining in this region. By 3 days after treatment, the Iba1-stained 
area was significantly greater than in the control brains, indicating significant alterations in the Iba1+ population 
(Fig. 6B). The same was true of GFAP staining at 3 days, which again was significantly higher in the treated brains 
than in the control brains (Fig. 6C and D).
Discussion
In this study, we have shown that topical Aldara treatment induces a potent chemokine and cytokine response 
throughout the peripheral tissues and in the brain, and that these responses are temporally distinct. The active 
component of Aldara cream, TLR7/8 antagonist IMQ, reaches the plasma and the brain within 4 hours of treat-
ment, and appears to reach equilibrium at around 12 hours post-application. The concentration of IMQ in the 
brain was positively and significantly correlated with that of the plasma and reached molar concentrations of 
0.33 μM in the plasma with a total load of 0.76 nmol in the brain at 3 days. Furthermore, direct entry of IMQ into 
the brain induces a reactive state of microglia and astrocytes, likely mediated through direct TLR7 activation. Our 
data suggest that the systemic effects of topical Aldara treatment are mediated through direct TLR7 stimulation.
While the systemic organs showed a rapid response, with significant upregulation of chemokine and cytokine 
transcripts by four hours, the transcriptional response began to ameliorate quickly and many of the cytokines and 
chemokines returned to control levels between day 1 and day 3. In contrast, whilst there was a moderate upreg-
ulation of some of the genes at the earlier time points, the peak of the brain response was at day 3. This was also 
true of the protein expression, where day 3 appeared to be the peak of the chemokine and cytokine response in 
the brain. It is important to mention there was some disparity between measured transcript and protein levels of 
CXCL1 and CCL11, however it is possible the higher protein induction was the result of the release of pre-stored 
cytoplasmic granules14 or peripheral sources entering the brain, as has been shown for many cytokines15. We had 
previously hypothesised that the delayed brain response may be due to the length of time it takes for the brain to 
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be activated from a distal application site9. However, the results of the mass spectrometry would suggest otherwise 
since detectable levels of IMQ were identified at 4 hours after application. In this study we clearly identified that 
the response in the brain was more prolonged than that of the periphery. Interestingly, the anti-inflammatory 
molecule IL-10 is only upregulated in the brain 3 days after the application of Aldara, whereas in 3 out of 4 
peripheral tissues examined, IL-10 was significantly induced by 4 hours. Thus one potential explanation for 
Figure 3. Topical Aldara application induces a chemokine transcriptional response at the local site of 
application and within the PBLs, Lungs and Liver. QRT-PCR analysis was performed on PBLs and perfused 
skin, lung and liver samples from mice treated daily with Aldara or control cream. Samples were collected 
4 hr, 12 hr, 1 d, 3 d and 5 d after the initial treatment. The expression profile of 3 chemokines was assessed in 
(A) Skin (B) PBL (C) Liver and (D) Lungs. Expression values were normalised to housekeeping gene Tbp. 
Data are presented as mean (+/−SD) fold changes vs respective controls. N = 4 mice per group. Data were 
log transformed and significance was determined using one-way ANOVA with post-hoc Student’s t-test with 
Bonferroni’s multiple testing correction. *P < 0.05; **P < 0.01; ***P < 0.001.
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the temporally unique brain response is the delayed onset of pro-resolution factors. Indeed, IL-10 induction is 
thought to be important for regulatory immunosuppression following TLR7 stimulation16 and IL-10-deficient 
mice showed higher pro-inflammatory cytokine levels following I.P LPS administration17.
Figure 4. Topical Aldara application induces a cytokine transcriptional response at the local site of application 
and within the PBLs, Lungs and Liver. QRT-PCR analysis was performed on PBLs and perfused skin, lung and 
liver samples from mice treated daily with Aldara or control cream. Samples were collected 4 hr, 12 hr, 1 d, 3 d 
and 5 d after the initial treatment. The expression profile of 3 cytokines was assessed in (A) Skin (B) PBL (C) 
Liver and (D) Lungs. Expression values were normalised to housekeeping gene Tbp. Data are presented as mean 
(+/−SD) fold change vs respective controls. N = 4 mice per group. Data were log transformed and significance 
was determined using one-way ANOVA with post-hoc Student’s t-test with Bonferroni’s multiple testing 
correction. *P < 0.05; **P < 0.01; ***P < 0.001.
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The results of the mass spectrometry experiment have provided a great deal of clarity regarding the brain 
response we have previously reported. With IMQ entering the brain so rapidly after treatment, it is likely that 
brain-resident, TLR7-expressing cells are the primary mediators of the brain response. This is particularly true 
Figure 5. Topical Aldara application results in entry of the TLR7 agonist imiquimod into the plasma and 
brain of mice as early as four hours after treatment. Mass spectrometry analysis was performed on plasma and 
perfused brains of mice treated daily with Aldara or control cream. Imiquimod levels were assessed (A) 24 hours 
after 3 daily treatments (N = 8 mice per group) and (B) 4 hr, 12 hr and 24 hr after a single treatment (N = 4 mice 
per group). (C) Linear regression analysis on matched plasma and brain samples was performed. Box represents 
25–75th percentile and whiskers represent min and max values. Significance was determined using (A) Student’s 
t-test (B) One-way ANOVA with post-hoc Student’s t-test with Bonferonni’s multiple testing correction. (C) 
Linear regression analysis. *P < 0.05; **P < 0.01; ***P < 0.001.
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considering earlier work has demonstrated that significant recruitment of immune cells to the CNS does not 
appear to occur within the first 24 hours9. This direct activation would explain the type I IFN response we have 
observed at both the transcriptional and protein levels and allows us to understand how other reported brain 
changes may have manifested. Aldara application induced protein expression of IFNb and IFNg in the brain 
between 1 and 3 days after treatment. In addition, protein levels of pro-inflammatory cytokines IL-1b and TNFa 
were significantly increased in the brain, both of which, along with IFNg, are known to activate IDO, facili-
tating the breakdown of the serotonin precursor, tryptophan. These findings are interesting in the context of 
previously identified reductions in burrowing behaviour, an indicator of anhedonia, as cytokines are known to 
induce sickness behaviours in rodents9,18. In addition, cytokines can decrease brain-derived neurotrophic factor 
Figure 6. Topical Aldara application induces significant changes in Iba1+ and GFAP+ cells in the hippocampus. 
Immunohistochemistry was performed on formalin-fixed paraffin embedded brain sections from mice treated 
daily with Aldara or control cream. Samples were collected 24 hr after first treatment and 24 hr after 3 daily 
treatment. (A) Representative images of Iba1+ staining in mouse hippocampus. (B) Quantification of Iba1+ 
area in mouse hippocampus. (C) Representative images of GFAP+ staining in mouse hippocampus. (D) 
Quantification of GFAP+ area in mouse hippocampus. Quantification was performed using ImageJ analysis 
software. Significance was determined using one-way ANOVA with post-hoc Student’s t-test with Bonferroni’s 
multiple testing correction. *P < 0.05; **P < 0.01; ***P < 0.001.
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(BDNF), adversely affecting neurogenesis and neuroplasticity19,20. Again, this is interesting in the context of our 
previous findings, as we have shown that topical Aldara treatment is associated with a reduction in hippocampal 
neurogenesis.
While research into brain specific effects of TLR7 is limited, Butchi et al. investigated the brain response to 
TLR stimulation using intracerebroventricular (i.c.v) injection of IMQ directly into the CNS of neonates21,22. 
They performed a dose response using concentrations of IMQ ranging from 20nmol per mouse to 500nmol 
per mouse and observed an upregulation of inflammatory cytokines and chemokines at all doses, 12 hours after 
injection. Whilst the response to TLR7 agonists was not nearly as potent as other TLR ligands, including CpG 
and LPS, IMQ injection induced a cellular response characterised by infiltrating leukocytes and the activation 
of brain-resident glial cells. Interestingly, Butchi et al. administered considerably higher doses of IMQ into the 
brain than we would have achieved using the topical Aldara model; however the response we see is arguably 
more extensive than that which they have reported. This may be due to an exaggerated immune response in the 
brain when accompanied by peripheral immune stimulation, a phenomenon sometimes referred to as ‘prim-
ing’23. Evidence of this has been shown in rodent models of prion disease and aged mice, where additional LPS 
stimulation exacerbates CNS inflammation by sensitising immune cells24,25. In addition, in early skin graft studies 
of immune privilege within the CNS, peripheral immune stimulation was shown to be a key event for inducing 
effective CNS immune responses26.
Aldara cream is used clinically for the treatment of genital warts, small superficial skin cancers and actinic 
keratosis, mimicking a viral infection to induce a potent anti-viral response. Whilst the dose for human use is 
significantly lower by body weight than that used in this mouse model, it is important to consider the potential 
consequences of long term use with the knowledge that IMQ has the ability to reach the CNS in rodents. Whilst 
it is not possible to assess the capacity of IMQ to enter the human brain, studies have shown that absorption 
through the skin can lead to measurable concentrations of IMQ in both the serum and urine27. Indeed, there are a 
number of case studies demonstrating that IMQ treatment can induce unintended systemic side effects that range 
in severity and frequency, including fever, fatigue, headaches and raised erythrocyte sedimentation rate28. Bearing 
in mind these systemic effects, and taking into consideration the small molecular weight (240.3 g/mol) and lipo-
philic nature of IMQ, it is feasible that circulating IMQ could enter the human brain with similar efficiency as 
it does in rodents. One consideration for this rodent model is the possibility of an oral route of absorption as 
described by Grine et al. However, considering that IMQ has been detected in human pharmacological studies 
where IMQ will not have been ingested we propose that, although this may contribute, topical absorption will 
occur and allow entry to the bloodstream regardless of oral ingestion of Aldara cream.
A considerable challenge in neuroimmunology is the ability to introduce immune stimuli into the CNS 
using non-infectious agents in a non-invasive manner. In this study we have identified that topically applied 
IMQ can directly enter the CNS and, as such, this provides an alternative tool for the study of neuroimmune 
responses to TLR stimulation that does not require i.c.v injections. In addition, as it is introduced through a 
peripheral route, it is likely to be more biologically relevant than i.c.v injections that are generally considered to 
be a non-physiological method of introducing agents into the CNS. The results presented in this study highlight 
the need for greater caution when interpreting the response to topical IMQ treatment, particularly in the context 
of psoriasis.
Methods
Animals. Female C57BL/6 mice were obtained from Harlan Laboratories/Envigo and were maintained at the 
Glasgow University Central Research Facility. Mice were kept for one week prior to commencement of proce-
dures to allow for acclimatisation and were maintained in specific pathogen-free conditions. Mice were treated 
between 8–9 weeks of age and were age- and sex- matched for each study. All experiments received local ethical 
approval and were performed in accordance with the animal care and welfare protocols approved by the Animal 
Welfare and Ethical Review Board at the University of Glasgow and were carried out under the auspices of a UK 
Home Office Project Licence.
Aldara Timecourse Model. 8–9 week old C57BL/6 female mice were treated with a quarter sachet 
(≈62.5 mg) of Aldara™ (Meda AB) cream containing 5% Imiquimod or an equivalent volume of control cream 
(Boots Aqueous Cream/10% Vaseline Lanette Cream) at each treatment point. Cream was applied to the shaved 
dorsal skin near the base of the tail and for time-points exceeding 24 hours mice were weighed daily. Mice were 
euthanised at 4 hours, 12 hours and 24 hours after the first treatment, or 24 hours after the 3rd and 5th treatment 
(4 h, 12 h, 1d, 3d, 5d groups respectively) with an increasing concentration of CO2.
Tissue Collection for RNA and protein. Blood was collected from mice immediately after euthanasia 
using a syringe flushed with 0.5 M EDTA. In brief, PBLs were obtained by separating the plasma and cellular 
compartments using centrifugation at 300 g for 10 minutes. Plasma was removed from the sample and red cell 
lysis treatment was performed for 10 minutes with ammonium chloride (STEMCELL Technologies). PBLs were 
re-suspended in buffer RLT (Qiagen) and stored at −80 °C.
Following blood collection, mice were perfused with 20 ml PBS through the left ventricle to clear the tissues. 
Following perfusion tissues (skin, lungs, liver and brain) were collected, placed in cryovials and snap frozen in 
liquid nitrogen. Tissues were stored at −80 °C until RNA extraction was performed.
Tissue Collection for FFPE Sections. The left hemisphere of the brain was collected from mice after 
euthanasia and placed into 10% neutral buffered formalin for 24–48 hours before being transferred to 70% etha-
nol prior to tissue processing. Samples were processed using a KOS microwave HistoSTATION (Milestone SRL) 
before being embedded in paraffin wax.
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Tissue Collection for Mass Spectrometry. After opening the right atrium, whole blood was collected 
in syringes flushed with lithium-heparin PBS before being placed into 1.5 ml Eppendorf containing 40 ul 
lithium-heparin PBS (8U lithium-heparin). Mice were subsequently perfused with 20 ml lithium-heparin PBS 
and brains were collected, placed in cryovials and snap frozen in liquid nitrogen. Plasma was immediately col-
lected from whole blood using two rounds of centrifugation at 10,000 g for 5 minutes. Both plasma and brains 
were stored at −80 °C until shipping on dry ice.
QRT-PCR. PBL and tissues were collected as described. Under RNase-free conditions, tissues were homog-
enized using the TissueLyser LT (Qiagen) in 1 ml of Qiazol® (Qiagen). RNA was isolated from PBL and tissue 
supernatants using the RNeasy Mini Kit (Qiagen) with DNase I (Qiagen) on-column treatment as per the manu-
facturer’s instructions. RNA quality was assessed using an Agilent Bioanalyzer (Agilent Technologies) at Glasgow 
Polyomics. RNA was converted to cDNA using High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific) 
as per the manufacturer’s instructions. cDNA concentration was standardized by using an equal quantity of 
RNA (measured using a Nanodrop). qRT-PCR was performed using QuantStudio7 (ThermoFisher Scientific) 
qRT-PCR machines. PerfeCTa SYBR Green FastMix with ROX reference dye (QuantaBio) was used for all reac-
tions. Samples were run in triplicate on 384 Well PCR Plates (Starlab) and were quantified using a 6-point stand-
ard curve. Analysis was performed following a series of quality control steps and gene expression was calculated 
relative to the housekeeping gene, Tbp.
LegendPlex Protein Assay. Protein was extracted from perfused brain tissue using N-PER neuronal 
extraction reagent (Thermo Fisher Scientific) as per manufacturer’s instructions. Homogenate was centrifuged 
at 10,000 g for 10 minutes at 4 C and supernatant was collected, snap frozen on dry ice and stored at −80 °C 
prior to use. Protein quality was assessed using western blot against the housekeeping protein GAPDH to ensure 
degradation had not occurred. Protein concentration was determined using Pierce BCA Protein Assay Kit 
(ThermoFisher Scientific, MA, USA) as per manufacturer’s instructions. Cytokine and chemokine expression 
in plasma and brain supernatant was measured using the LegendPlex protein assay (BioLegend). In brief, beads 
were incubated with protein extract for 2 hours at 600 rpm on a plate shaker. Beads were then conjugated with 
streptavidin-phycoerythrin (SA-PE) for 30 minutes and two washes were performed prior to sample reading 
using a BD LSR-II flow cytometer (BD Biosciences). Samples were differentiated on the basis of bead size and 
APC fluorescence, while protein quantity was determined using SA-PE fluorescence calibrated to a standard 
curve.
Mass Spectrometry. Plasma and brain samples were sent to the Biomarker and Drug Analysis Core Facility 
at the University of Dundee (http://medicine.dundee.ac.uk/biomarker-and-drug-analysis-core-facility) for mass 
spectrometry analysis. Briefly, samples were homogenized and subjected to solid phase extraction using in-house 
strong cation exchange SpinTip. Eluents were dried and then reconstituted in 25 μL elution solution. Liquid chro-
matography coupled with tandem mass spectrometry was perfomed using a HILIC colum (Intersil, GL Sciences) 
and a Thermo Quantum Ultra mass spectrometer (ThermoFisher Scientific). The lower limit of quantification was 
1.57 ng/mL. Full mass spectrometry methods are provided in the supplementary information.
Immunohistochemistry. Brains were cut to 5 μm sagittal sections using a Shandon Finesse 325 Microtome 
(Thermo Fisher Scientific) and were stained for Iba1, GFAP or appropriate isotypes and negative controls. Three 
non-consecutive slides were stained for each cell type from each mouse brain. Blinded slides were sent to the 
Beatson Institute (University of Glasgow) to be scanned. Iba1 and GFAP hippocampal area quantification was 
carried out using ImageJ software.
Statistical analysis. All statistical analysis was performed in GraphPad Prism 7 software. Gene and pro-
tein expression data were log transformed prior to parametric tests. Student’s t-test or one-way ANOVA (with 
post-hoc tests) were used to test for significant differences between groups as indicated in the figure legend. 
If multiple genes or time points were tested in the same experiment, Bonferroni’s multiple correction testing 
was applied to account for the increased probability of type I errors. Linear regression analysis was performed 
to determine the association between plasma and brain imiquimod levels. A p-value of <0.05 was considered 
significant.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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